Magle Chemoswed Holding AB (publ) (MAGLE.ST) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. MAGLE.ST files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4992.20% | 30.00% | Fail |
| Interest-bearing investments | 162.74% | 30.00% | Fail |
| Non-permissible income | 0.11% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 50.78% | 33.00% | Fail |
| Interest-bearing investments | 1.66% | 33.00% | Pass |
| Non-liquid assets | 93.60% | at least 20.00% | Pass |
| Non-permissible income | 0.11% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 50.78% | 33.33% | Fail |
| Cash + interest-bearing securities | 1.66% | 33.33% | Pass |
| Accounts receivable | 6.40% | 33.33% | Pass |
| Non-permissible income | 0.11% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 50.78% | 33.33% | Fail |
| Cash + interest-bearing securities | 1.66% | 33.33% | Pass |
| Accounts receivable | 6.40% | 50.00% | Pass |
| Non-permissible income | 0.11% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 109.98% | 33.00% | Fail |
| Cash + interest-bearing securities | 3.59% | 33.00% | Pass |
| Accounts receivable | 10.28% | 33.00% | Pass |
| Non-permissible income | 0.11% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 111.90% | 33.00% | Fail |
| Cash + interest-bearing securities | 3.65% | 49.00% | Pass |
| Accounts receivable | 10.46% | 49.00% | Pass |
| Non-permissible income | 0.11% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 111.90% | 33.33% | Fail |
| Cash + interest-bearing securities | 3.65% | 33.33% | Pass |
| Accounts receivable | 14.11% | 49.00% | Pass |
| Non-permissible income | 0.11% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 37.60 | NEUTRAL |
| Stochastic %K (14) | 51.43 | NEUTRAL |
| CCI (20) | -63.61 | NEUTRAL |
| Williams %R (14) | -48.57 | NEUTRAL |
| MACD (12,26,9) | 0.03 | BUY |
| ROC (10) | -14.80 | SELL |
| Momentum (10) | -0.07 | SELL |
| EMA (10) | 0.39 | SELL |
| SMA (10) | 0.38 | BUY |
| EMA (20) | 0.43 | SELL |
| SMA (20) | 0.41 | SELL |
| EMA (30) | 0.52 | SELL |
| SMA (30) | 0.43 | SELL |
| EMA (50) | 0.87 | SELL |
| SMA (50) | 0.66 | SELL |
| EMA (100) | 2.48 | SELL |
| SMA (100) | 1.89 | SELL |
| EMA (200) | 7.26 | SELL |
| SMA (200) | 6.81 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Magle Chemoswed Holding AB (publ) engages in researching, developing, and manufacturing in the areas of medicinal chemistry and pharmaceutical technology in Sweden, Switzerland, rest of Europe, the United States, Brazil, and internationally. It offers degradable starch microsphere and dextran products; and active pharmaceutical ingredients, as well as engages in the research, development, manufacture, market, and sale of diagnostics products to hospitals, clinics, and pharmacies; and contract development and manufacturing organization activities. The company also provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, an antipsychotic agent; and isradipine, a calcium channel blocker used to treat hypertension. In addition, it offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures. Further, the company is developing EmboCept M for the treatment of benign prostatic hyperplasia; EmboCept L for the treatment of uterine fibroids; SmartGel II, an advanced wound care hydrogel for the removal and prevention of wound biofilm; and SmartBone, an advanced formulation of microspheres in combination with active ingredients for stimulation of bone growth in surgical implant procedures. Additionally, it develops and produces stem cell-based therapies for investigational and GMP use; and provides consulting services in materials and solid phase analysis services. Magle Chemoswed Holding AB (publ) was founded in 1944 and is based in Malmö, Sweden.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.